IBA and Philips to collaborate on cancer research and technology

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Ion Beam Applications (IBA) announced today that the company will be teaming up with Philips Healthcare to develop new diagnostic and therapeutic research and technology, including proton therapy systems.

The international agreement covers mutual use and development of image guidance and other technology and cancer therapy centers across the globe. IBA will specifically be able to work with Philips diagnostic imaging systems and Philips will be able to able to provide IBA’s proton therapy systems in a selection of markets.

As an integrated partnership, the two companies also will be setting up molecular imaging centers that merge Philips imaging with IBA PET radioisotope production.

“This is an exciting and important step for IBA,” said Olivier Legrain, chief executive officer of IBA, in the press release. “A closer collaboration with a company of Philips’ caliber and global reach, where we are able to combine both companies’ expertise and excellence in oncology care, will accelerate innovation and provide more efficient and effective solutions in molecular imaging and treatment solutions."

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.